Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad5 EBOV DNA vaccine - Academy of Military Medical Sciences/Tianjin CanSino

Drug Profile

Ad5 EBOV DNA vaccine - Academy of Military Medical Sciences/Tianjin CanSino

Alternative Names: Ad5 vector based Ebola vaccine - Academy of Military Medical Sciences/Tianjin CanSino; Ad5-EBOV; Ebola adenovirus vector vaccine - Academy of Military Medical Sciences/Tianjin CanSino; Ebola adenovirus vector vaccine - Tianjin CanSino/Academy of Military Medical Sciences; Ebola Zaire vaccine - Academy of Military Medical Sciences/Tianjin CanSino; Ebola Zaire vaccine - Tianjin CanSino/Academy of Military Medical Sciences

Latest Information Update: 01 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academy of Military Medical Sciences; Tianjin CanSino Biotechnology
  • Developer Academy of Military Medical Sciences; Beijing Institute of Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention; Tianjin CanSino Biotechnology; Zhejiang University
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ebola virus infections

Most Recent Events

  • 01 Oct 2021 No development reported - Phase-II for Ebola virus infections (Prevention, In volunteers) in Sierra Leone (IM)
  • 20 Oct 2017 Registered for Ebola virus infections (Prevention) in China (IM)
  • 01 Jul 2016 Jiangsu Province Centers for Disease Control and Prevention completes a phase-II trial in Ebola virus infections (Prevention) in Sierra Leone (IM) (NCT02575456)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top